Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Sees Revenue Drop, Increased Loss in Q1

SAN FRANCISCO, April 24 - Luminex on Wednesday posted decreased revenues and a widened loss for the first quarter 2002.

 

For the three months ended March 31, the company reported revenues of $2.3 million, compared with $3.9 million in the same period one year ago.

 

Luminex also said that net losses widened to $6.4 million, or $.22 a share in the first quarter of 2002, compared with $3.9 million, or $.14 a share one year ago.

 

"Although we fell short of our expectations for the first quarter, we remain extremely optimistic about the market acceptance of the Luminex platform," Mark Chandler, CEO of Luminex, said in a statement. "Our revenues continue to be negatively impacted by delays in the commercialization efforts of our strategic partners and the lengthy and unpredictable sales cycle for our company's products."

 

R&D spending decreased approximately $800,000 year-over-year to approximately $2 million.

 

Luminex said it has roughly $45 million in the bank.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.